Optional product analytics

With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.

ILMN · Published research archive | StockMarketAgent.AI

DiscoverOutlookToolsDevelopersCompany

ILMN · Archive

Read prior published editions, ratings, and price trends. Each row discloses its own analysis date.

2026Oct

ILMN Oct 2026 · Sell

Illumina is rated Sell with Fair value of $119.53 compared to $259.19, reflecting -53.9% upside.Latest published research · analyzed 2026-10-22 · current · sources fresh

Illumina remains the dominant player in genomic sequencing but is transitioning into a mature compounder phase. Having resolved recent antitrust distractions and returned to profitability in 2025, the company faces normalized mid-single-digit growth, requiring disciplined capital allocation and margin protection against emerging competitors.Historical archived edition · analyzed 2026-05-13

Sell

USD 145.70

StockMarketAgent

Methodologyv3.2

Product

Discover Coverage Earnings calendar Stock screener Stock lists Best stocks Markets Outlook Tools Data catalog Pricing Start free

Learn

Methodology Independent research Alternatives Glossary Learning paths Changelog Sample report FAQ

Research / Compare

Sectors Archetypes Outlook archive Compare stocks Alternatives Best stocks Stock screener Stock lists

Developers

Developers API docs Sandbox MCP launch status

Support Disclaimer Terms of service Privacy policy Editorial guidelines Corrections

Rating history

The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026

Sell